MoonLake Immunotherapeutics (MLTX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for MoonLake Immunotherapeutics (MLTX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 35/100 — a percentile rank of MoonLake Immunotherapeutics’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $976.2M |
| EV / EBITDA | -2.2× |
| Return on equity | -61.2% |
| ROIC | -541.0% |
| Debt / equity | 0.2× |
| Dividend yield | 0.0% |
Is MoonLake Immunotherapeutics overvalued? P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from MoonLake Immunotherapeutics’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact